From a lipid specialist perspective, how do you navigate the risk territory of LDL-C levels <70 mg/dL with PCSK9 inhibitors? And in which patient subgroups do these agents offer unique outcome-related benefits?

From a lipid specialist perspective, how do you navigate the risk territory of LDL-C levels <70 mg/dL with PCSK9 inhibitors? And in which patient subgroups do these agents offer unique outcome-related benefits?

CLICK HERE FOR CME CREDIT

From a lipid specialist perspective, how do you navigate the risk territory of LDL-C levels

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Professor of Medicine Division of Endocrinology, Metabolism & Lipid Research Washington University in St. Louis St. Louis, MO